Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CencoraWBO:ABC -0.22%68 Equity-to-Asset is 0.04 as of Mar. 2026, which is 100% above its 10-year median of 0.02. GuruFocus rates WBO:ABC with a GF Score™ of 68/100 and a GF Value™ of €254.62 (Fairly Valued). The stock has 1 warning sign investors should review. Among 120 Medical Distribution companies, Cencora ranks worse than 92.5% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cencora's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €2,939 Mil. Cencora's Total Assets for the quarter that ended in Mar. 2026 was €70,629 Mil.
Therefore, Cencora's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.04.
The historical rank and industry rank for Cencora's Equity-to-Asset or its related term are showing as below:
WBO:ABC'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02 Med: 0.02 Max: 0.1
Current: 0.04
During the past 13 years, the highest Equity to Asset Ratio of Cencora was 0.10. The lowest was -0.02. And the median was 0.02.
WBO:ABC's Equity-to-Asset is ranked worse than 92.5% of 120
companies
in the Medical Distribution industry
Industry Median: 0.385
vs WBO:ABC: 0.04
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cencora Equity-to-Asset Related Terms
Cencora Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cencora's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:ABC vs CAH, MCK, HSIC: Equity-to-Asset Comparison
For the Medical Distribution subindustry, Cencora's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora Equity-to-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cencora's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cencora's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora (WBO:ABC) has a Equity-to-Asset of 0.04 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cencora and its competitors. This is 100% above median its historical median of 0.02. According to the industry distribution chart, Cencora ranks #111 out of 120 companies in the Medical Distribution industry, placing it in the top 92.5%.
Is Cencora's Equity-to-Asset too high?
Cencora's current Equity-to-Asset of 0.04 is 100% above median its 10-year median of 0.02. The Medical Distribution industry median Equity-to-Asset is 0.39. Cencora's value of 0.04 is 89.6% below this industry median. Based on the distribution chart, Cencora ranks #111 out of 120 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cencora has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's Equity-to-Asset compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #111 out of 120 companies for Equity-to-Asset. This places Cencora in the lower half of its industry. The industry median Equity-to-Asset is 0.39. Cencora's value of 0.04 is 89.6% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.39, Cencora has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Distribution company?
The median Equity-to-Asset among Medical Distribution companies is 0.39, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cencora's current Equity-to-Asset of 0.04 is 89.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cencora and its competitors. For the Medical Distribution industry, the median Equity-to-Asset is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current Equity-to-Asset is 0.04, which is 100% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €254.62, compared to a current price of €270.20 — trading 6.1% above its estimated fair value. The current Equity-to-Asset is 0.04, which is 100% above median its 10-year median of 0.02 and 89.6% below the Medical Distribution industry median of 0.39. Cencora's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cencora (WBO:ABC), the current Equity-to-Asset is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be overvalued.
The current stock price of €270.20 is trading 6.1% above its estimated GF Value™ of €254.62.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
Equity-to-Asset: 0.04 (100% above median its 10-year median of 0.02)
GF Value™: €254.62 vs. price of €270.20 (6.1% above fair value)
Industry Position: 89.6% below the Medical Distribution median (#111 of 120)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
68GF Score
Get the complete analysis for WBO:ABC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 
